Chemist + Druggist is part of Pharma Intelligence UK Limited

This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.


This copy is for your personal, non-commercial use. Please do not redistribute without permission.

Printed By

UsernamePublicRestriction

Avicenna chief: Second wave of COVID-19 demand on pharmacies is coming

There will be a second wave of unprecedented demand on community pharmacies as a result of the COVID-19 pandemic, according to Avicenna chair Salim Jetha.

Mr Jetha predicts there will be another surge of patients into pharmacies caused by the knock-on health effects of halting of all face-to-face tests in pharmacies and GP surgeries across the UK during March.

Listen to the podcast to hear more, as well as Mr Jetha’s concerns about the spiralling costs of delivering medicines, the possibility of pharmacy closures and dispensing at a loss.

You can listen to the podcast below. Alternatively, subscribe to C+D's podcasts on iTunes or by searching “Chemist+Druggist podcast” on your preferred Android podcast app.

Please note, the sound quality of this podcast may be affected as it has been recorded remotely during the COVID-19 outbreak

To keep up with the latest updates for community pharmacy visit our COVID-19 hub.

Topics


         
Pharmacist
Yeovil, Winchester & Dorchester
£50-55,000 per annum

Apply Now
Latest News & Analysis
See All
UsernamePublicRestriction

Register

CD005194

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel